Autopsy report · NCT00437489
A Clinical Trial Comparing The Efficacy And Safety Of 2 Different Initial Dose Prescriptions For Exubera.
Cause of deathFunding or business
“This protocol was terminated not for safety reasons, but because Pfizer decided to return the worldwide rights for Exubera to Nektar, on 18 October 2007.”
Life of this trial
- Registered 4 months before it started.
- Ran for about 6 months before it stopped.
- 49 participants enrolled.
- Results were posted on the registry 1 year 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 4
- Sponsor
- Pfizer
- Sponsor type
- Industry
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Inhaled Human Insulin (Exubera); Inhaled Human Insulin (Exubera)
- Participants
- 49
- Sites
- 9
- Countries
- Hong Kong, Pakistan, Philippines, Singapore
Trials that died the same way
- Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
“A business decision was made by Pfizer to terminate and remove the Phase 2 expansion of this study for administrative reasons. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.